DoD-Supported Randomized Clinical Study of Electroceutical Dressing Technology Completes at Indiana University
Updated: 5 days ago
COLUMBUS, Ohio — July 7, 2023 — A randomized clinical study of Pavaka's Gen 1 electroceutical dressing technology has completed, according to its public record on ClinicalTrials.gov (NCT04794621). The platform was later exclusively licensed to Pavaka Wound Care.
The study, "Electroceutical Dressing Technology (EDT) Against Wound Microbial Biofilm Infection," was led by Indiana University, with the U.S. Department of Defense and the Naval Medical Research Center listed as collaborators. Sashwati Roy, PhD, served as principal investigator. The study began on June 3, 2021, and reached completion on July 7, 2023, with 112 participants enrolled.
Participants were randomly assigned to one of two parallel groups. To limit bias, the personnel who analyzed wound biofilm, the study's primary outcome, were blinded to which group each participant belonged to. The study was conducted at three Indianapolis-area sites: Eskenazi Health, the Richard L. Roudebush VA Medical Center, and Indiana University Health Methodist Hospital.
The electroceutical dressing technology generates a low-level electric field at the wound surface. It was developed by an interdisciplinary research team at The Ohio State University and is designed for use on chronic and acute wounds, where bacterial biofilms are a persistent clinical challenge. The randomized study followed an earlier 8-patient human feasibility study of the technology, published in Advances in Wound Care in 2019.
Completing a randomized study of this size is an important step for any new wound care technology. The investigators are preparing the results for peer-reviewed publication, and Pavaka will share findings once they are published.
Pavaka Wound Care launched later in 2023 to carry this body of research forward. Its goal is to turn a decade of academic and government-funded work into a manufacturable dressing that clinicians in civilian and military settings can eventually use.
Why it matters: biofilms are a major reason chronic wounds stall. These structured bacterial communities shield themselves from the immune system and from many conventional treatments. A randomized study design, with blinded analysis of the primary biofilm outcome, is the kind of rigorous evidence clinicians and regulators look for as they evaluate any new wound care technology.
"Few early-stage wound care technologies come to a company with a completed randomized study behind them. We owe that to the investigators, the participants and the Department of Defense, and our job now is to build on that work responsibly." — Brent Toto, CEO and Co-Founder
Investigational device: Pavaka's electroceutical wound dressing has not been cleared or approved by the U.S. Food and Drug Administration and is not available for sale.
About Pavaka Wound Care: Pavaka Wound Care is a Columbus, Ohio–based medical device company developing an electroceutical advanced wound dressing for chronic and acute wounds, including wounds complicated by multidrug-resistant bacteria and biofilms. Built on technology exclusively licensed from The Ohio State University, the investigational dressing generates a low-level electric field at the wound surface. Pavaka was co-founded by CEO Brent Toto and CTO Frank Fischer. Learn more at www.pavakawoundcare.com.




Comments